SCHEDULE OF PHARMACEUTICAL BENEFITS EFFECTIVE 1 JUNE 2026
ERRATUM

This erratum corrects the prescribing instructions of the drug Blinatumomab for item codes 11118E and 11116C in the 1 June 2026 Schedule of Pharmaceutical Benefits.

Efficient Funding of Chemotherapy (Private Hospital)

BLINATUMOMAB

Caution Careful monitoring of patients is required due to risk of developing life-threatening Cytokine Release Syndrome, neurological toxicities and reactivation of John Cunningham virus (JC) viral infection.

Note Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Services Australia website at www.servicesaustralia.gov.au

Applications for authority to prescribe should be submitted online using the form upload facility in Health Professional Online Services (HPOS) at www.servicesaustralia.gov.au/hpos

Or mailed to:

Services Australia

Complex Drugs

Reply Paid 9826

HOBART TAS 7001

Note No increase in the maximum quantity or number of units may be authorised.

Note No increase in the maximum number of repeats may be authorised.

Note Special Pricing Arrangements apply.

Authority Required

Acute lymphoblastic leukaemia

Treatment Phase: Induction treatment of relapsed or refractory B-precursor cell ALL

Clinical criteria:

- The condition must be relapsed or refractory B-precursor cell ALL, with an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less, **AND**
- The condition must not be present in the central nervous system or testis, **AND**
- Patient must not have received more than 1 line of salvage therapy, **AND**
- The condition must be one of the following: (i) untreated with this drug for Precursor B-cell acute lymphoblastic leukaemia (Pre-B-cell ALL), (ii) treated with this drug for Pre-B-cell ALL, but the condition has not relapsed within 6 months of completing that course of treatment, **AND**
- The condition must have more than 5% blasts in bone marrow; or
- The condition must have measurable residual disease based on measurement in bone marrow following complete remission, **AND**
- The treatment must not be more than 2 treatment cycles under this restriction in a lifetime

According to the TGA-approved Product Information, hospitalisation is recommended at minimum for the first 9 days of the first cycle and the first 2 days of the second cycle. For all subsequent cycle starts and re-initiation (e.g. if treatment is interrupted for 4 or more hours), supervision by a health care professional or hospitalisation is recommended.

An amount of 651 microgram will be sufficient for a continuous infusion of blinatumomab over 28 days in cycle 1. An amount of 784 microgram, which may be obtained under Induction treatment - balance of supply restriction, will be sufficient for a continuous infusion of blinatumomab over 28 days in cycle 2.

Blinatumomab is not PBS-subsidised if it is administered to an in-patient in a public hospital setting.

The authority application must be made in writing and must include:

(1) details of the proposed prescription;

(2) a completed Acute Lymphoblastic Leukaemia in complete haematological remission PBS Authority Application - Supporting Information Form;

(3) date of most recent chemotherapy (if applicable), and if this was the initial chemotherapy regimen or salvage therapy;

(4) for Philadelphia chromosome positive patients: (i) the date of the most recent treatment with a TKI (in combination with chemotherapy); OR (ii) if applicable the date of initial combined treatment with TKI and corticosteroids (if unable to tolerate chemotherapy);

(5) if applicable, the date of completion of blinatumomab treatment for Pre-B-cell ALL in complete remission and the date of the patient's subsequent relapse, AND

(6) the percentage blasts in bone marrow count measured that is no more than 4 weeks old at the time of application.

Injection

11116C

Max. Amount	No. of Rpts	Premium $	DPMA $	MRVSN $	Brand Name and Manufacturer
651 mcg	0	0.00	*67292.74	25.00	Blincyto [AN] (blinatumomab 38.5 microgram injection [1 vial] (&) inert substance solution [10 mL vial], 1 pack)

Efficient Funding of Chemotherapy (Private Hospital)

BLINATUMOMAB

Caution Careful monitoring of patients is required due to risk of developing life-threatening Cytokine Release Syndrome, neurological toxicities and reactivation of John Cunningham virus (JC) viral infection.

Note Any queries concerning the arrangements to prescribe may be directed to Services Australia on 1800 700 270 (hours of operation 8 a.m. to 5 p.m. Monday to Friday).

Prescribing information (including Authority Application forms and other relevant documentation as applicable) is available on the Services Australia website at www.servicesaustralia.gov.au

Applications for authority to prescribe should be submitted online using the form upload facility in Health Professional Online Services (HPOS) at www.servicesaustralia.gov.au/hpos

Or mailed to:

Services Australia

Complex Drugs

Reply Paid 9826

HOBART TAS 7001

Note No increase in the maximum quantity or number of units may be authorised.

Note No increase in the maximum number of repeats may be authorised.

Note Special Pricing Arrangements apply.

Authority Required

Acute lymphoblastic leukaemia

Treatment Phase: Induction treatment of relapsed or refractory B-precursor cell ALL

Clinical criteria:

- The condition must be relapsed or refractory B-precursor cell ALL, with an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less, **AND**
- The condition must not be present in the central nervous system or testis, **AND**
- Patient must not have received more than 1 line of salvage therapy, **AND**
- The condition must be one of the following: (i) untreated with this drug for Precursor B-cell acute lymphoblastic leukaemia (Pre-B-cell ALL), (ii) treated with this drug for Pre-B-cell ALL, but the condition has not relapsed within 6 months of completing that course of treatment, **AND**
- The condition must have more than 5% blasts in bone marrow;or
- The condition must have measurable residual disease based on measurement in bone marrow following complete remission, **AND**
- The treatment must not be more than 2 treatment cycles under this restriction in a lifetime

According to the TGA-approved Product Information, hospitalisation is recommended at minimum for the first 9 days of the first cycle and the first 2 days of the second cycle. For all subsequent cycle starts and re-initiation (e.g. if treatment is interrupted for 4 or more hours), supervision by a health care professional or hospitalisation is recommended.

An amount of 651 microgram will be sufficient for a continuous infusion of blinatumomab over 28 days in cycle 1. An amount of 784 microgram, which may be obtained under Induction treatment - balance of supply restriction, will be sufficient for a continuous infusion of blinatumomab over 28 days in cycle 2.

Blinatumomab is not PBS-subsidised if it is administered to an in-patient in a public hospital setting.

The authority application must be made in writing and must include:

(1) details of the proposed prescription;

(2) a completed Acute Lymphoblastic Leukaemia in complete haematological remission PBS Authority Application - Supporting Information Form;

(3) date of most recent chemotherapy(if applicable), and if this was the initial chemotherapy regimen or salvage therapy;

(4) for Philadelphia chromosome positive patients: (i) the date of the most recent treatment with a TKI (in combination with chemotherapy); OR (ii) if applicable the date of initial combined treatment with TKI and corticosteroids (if unable to tolerate chemotherapy);

(5) if applicable, the date of completion of blinatumomab treatment for Pre-B-cell ALL in complete remission and the date of the patient's subsequent relapse, AND

(6) the percentage blasts in bone marrow count measured that is no more than 4 weeks old at the time of application.

Injection

11118E

Max. Amount	No. of Rpts	Premium $	DPMA $	MRVSN $	Brand Name and Manufacturer
651 mcg	0	0.00	*66319.95	25.00	Blincyto [AN] (blinatumomab 38.5 microgram injection [1 vial] (&) inert substance solution [10 mL vial], 1 pack)